OnDemand WTP Pricing Research

JP Morgan preview – price hikes come back with a bang in 2019 | Evaluate

If 2018 was the year of biopharma pricing temperance it looks like the industry is back to business as usual for 2019. Several biopharma companies rang in the New Year with price hikes, and investors will watch out for more at next week’s JP Morgan healthcare conference.

The conference, often described as the barometer for the year ahead, could also see more details on Pfizer’s 2019 pricing strategy under a new chief executive, Albert Bourla, presenting on Monday morning. In November the company said it would put up the cost of 10% of its portfolio, or around 41 drugs.

Merck & Co soon followed Pfizer’s lead – and now Allergan, Biogen, Bristol-Myers Squibb and Lilly have done the same, as predicted by Vantage (US price truce cracks but biopharma may want to tread carefully, November 30, 2018).

It appears that Donald Trump’s infamous tweet in July, aimed at Pfizer “and others”, only helped postpone price hikes rather than stopping them entirely. The president might try to rain on the industry’s parade as he did at JP Morgan 2017, when comments he made during a press conference rocked biopharma stocks, but since then he has seemingly lost his power to hurt the industry.

Read complete article here:

JP Morgan preview – price hikes come back with a bang in 2019 | Evaluate.

Post a Comment

WP-SpamFree by Pole Position Marketing